CREST: EFS Subgroup Analyses Based on Disease Stage

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai, and Karine Tawagi, MD, University of Illinois, detail the event-free survival subgroup analyses based on disease stage from the CREST study, which investigated sasanlimab in combination with BCG in BCG-naive, high-risk NMIBC.

This post hoc analysis adds further support for the potential of sasanlimab in combination with BCG as a practice-changing treatment in patients with aggressive disease.
Category
Oncology
Be the first to comment

Up Next